Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.56 |
| ▸ | MTOR | P42345 | 11/20 | 0.51 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12499215 | 0.87 | PIK3CA (0.55) | PIK3CAMTORPIK3R1 | |
| SCHEMBL12499426 | 0.86 | PIK3CA (0.53) | PIK3CAMTOR | |
| SCHEMBL12499830 | 0.85 | PIK3CA (0.77) | PIK3CAMTORPIK3R1PIK3CDPIK3CB | |
| SCHEMBL12498527 | 0.83 | PIK3CA (0.62) | PIK3CAMTORPIK3CG | |
| SCHEMBL15378682 | 0.80 | PIK3CA (0.71) | PIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL12499356 | 0.73 | PIK3CA (0.82) | PIK3CAMTORPIK3CG | |
| SCHEMBL18660588 | 0.73 | PIK3CA (0.62) | PIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL1409540 | 0.71 | PIK3CA (0.54) | PIK3CAMTORPIK3R1PIK3CG | |
| SCHEMBL1309097 | 0.71 | PIK3CA (1.00) | PIK3CAMTORPIK3R1PIK3CDPIK3CB | |
| SCHEMBL12499631 | 0.71 | PIK3CA (0.73) | PIK3CAMTORPIK3R1PIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | claimed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | claimed |
| WO-2012101654-A2 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-08-02 | — | — | WO | claimed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, MAPKAP1, PIK3R5 | PIK3CA 13/4885MTOR 1/4885PIK3R1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.